Get the Stockscreener App
1.75
1.13%
-0.02
Pre-market:
1.75
Biovie Inc stock is traded at $1.75, with a volume of 63,844.
It is down -1.13% in the last 24 hours and down -7.89% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.77
Open:
$1.77
24h Volume:
63,844
Relative Volume:
0.22
Market Cap:
$13.18M
Revenue:
-
Net Income/Loss:
$-25.56M
P/E Ratio:
-0.3365
EPS:
-5.2
Net Cash Flow:
$-19.35M
1W Performance:
-6.91%
1M Performance:
-7.89%
6M Performance:
+114.01%
1Y Performance:
-36.13%
1-Day Range:
$1.70
$1.79
1-Week Range:
$1.70
$1.95
52-Week Range:
$0.62
$9.56
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.75 | 13.34M | 0 | -25.56M | -19.35M | -5.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
Analyzing recovery setups for BioVie Inc. investorsJuly 2025 Retail & Weekly High Return Stock Opportunities - newser.com
Momentum divergence signals in BioVie Inc. chartBond Market & Safe Capital Investment Plans - newser.com
Key metrics from BioVie Inc.’s quarterly data2025 Valuation Update & Safe Capital Growth Tips - newser.com
Identifying reversal signals in BioVie Inc.Fed Meeting & Safe Capital Investment Plans - newser.com
Can volume confirm reversal in BioVie Inc.Portfolio Update Summary & Stepwise Entry and Exit Trade Signals - newser.com
Chart based exit strategy for BioVie Inc.2025 Support & Resistance & Technical Confirmation Trade Alerts - newser.com
Using data filters to optimize entry into BioVie Inc.2025 Top Decliners & Community Verified Trade Alerts - newser.com
Using Ichimoku Cloud for BioVie Inc. technicalsOil Prices & Free Technical Pattern Based Buy Signals - newser.com
BioVie Inc Stock Analysis and ForecastStock Split Announcements & Affordable Stock Picks - earlytimes.in
Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Holland Sentinel
Is it time to cut losses on BioVie Inc.July 2025 Earnings & Reliable Volume Spike Alerts - newser.com
Is BioVie Inc. stock oversold or undervaluedMarket Growth Report & Weekly Top Gainers Alerts - fcp.pa.gov.br
BioVie Inc.’s NE3107: A Promising Study for Long COVID Relief - TipRanks
BioVie Inc.’s NE3107 Study: A New Hope for Early Parkinson’s Treatment - TipRanks
Is BioVie Inc. stock a safe haven asset2025 Year in Review & Safe Entry Momentum Stock Tips - fcp.pa.gov.br
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):